Mursla company

Based in Cambridge (UK), Mursla is a startup developing a diagnostic device that leverages proprietary nanostructures to significantly improve cancer detection. Our technology has the potential to simplify the whole cycle of cancer management through utilizing a novel, non-invasive procedure called liquid biopsy.
We provide a competitive and differentiated proposal with superior predictive power potential by identifying panels of circulating wild-type and mutant proteins in blood at the point-of-care. Proteins are the key mediators of regulated or unregulated cellular activities in contrast to circulating nucleic acids assessed by Next-Gen Sequencing Technologies.
Technology: P4 Medicine
Industry: Preventive Medicine
Headquarters: Cambridge, Cambridgeshire, United Kingdom
Founded Date: 2017
Employees Number: 11-50
Funding Status: Seed
Total Funding: $2M
Last Funding Type: Seed

Visit Website
Register and Claim Ownership